Elanco Posts 10% Organic Growth and Becomes the #2 Stealing Share

Q1 2026 organic constant-currency revenue at Elanco Animal Health (NYSE: ELAN) grew 10%, the company beat consensus EPS, and management raised full-year guidance. Credelio Quattro is "accelerating market share gains" and Zenrelia just hit trailing-four-quarter blockbuster status. In a quarter where Zoetis' US companion animal segment fell 11%, the print confirms the parasiticide and dermatology share war is no longer hypothetical.

Elanco Q1 organic up 10%, FY26 guide raised

Q1 2026 revenue at Elanco was $1.371 billion, up 15% reported and 10% organic constant-currency, with growth split 2% price and 8% volume. Adjusted EPS came in at $0.40, beating the $0.34 consensus.

Management raised full-year 2026 guidance: revenue growth of 5% to 7%, up from 4% to 6%. Adjusted EBITDA is now guided to $975 million to $1.005 billion, adjusted EPS to $1.03 to $1.09. Innovation revenue guidance went up $50 million to $1.2 billion.

The growth drivers cited were specific. Credelio Quattro, the all-in-one canine parasiticide, posted "accelerating market share gains." Zenrelia, the daily JAK inhibitor for canine pruritus, reached trailing-four-quarter blockbuster status. All major species grew across innovation contribution and base business.

The print landed one day before Zoetis reported flat organic revenue and an 11% decline in US companion animal sales. Zoetis specifically named competitive pressure on its dermatology franchise and Simparica Trio.

The two reads of the quarter are now sitting side by side. One company is gaining share. The other is losing it.

Why Elanco is now the share-stealer in animal health

For most of the last decade, animal health was a Zoetis-vs-itself story. Elanco was the troubled #2 — post-spin from Eli Lilly, leveraged, working through integration debt. Q1 is the clearest signal yet that the competitive dynamic has flipped.

1. Parasiticides are now a real share war. Credelio Quattro adds tapeworm coverage to the standard flea, tick, and heartworm bundle, putting it head-to-head with Simparica Trio. Zoetis explicitly named Simparica Trio as a US weakness. Elanco's "accelerating market share gains" the same week is the share moving. For pet brands modeling parasiticide attach and pet insurers modeling Rx cost trends, the assumption that one molecule dominates is wrong.

2. Zenrelia is the first credible competitor to Apoquel at scale. Apoquel powered Zoetis dermatology for a decade. Trailing-four-quarter blockbuster status for Zenrelia means Elanco has put a billion-dollar competitor on the shelf in less than two years from launch. Vets are switching. The "gold standard" framing that worked through 2024 doesn't sell the same way in 2026.

3. The innovation guide raise is a credibility move. Elanco has historically been judged on whether new product revenue would actually compound. Raising the innovation guide one quarter into the year, alongside share-gain commentary, pulls forward the case that the launches stick. Operators should price the medium-term landscape as a contested category, not a duopoly drift.

4. Volume is doing the work, not price. Q1 organic split 2% price, 8% volume. Volume growth that exceeds price growth is the cleanest signal that share is coming with the launches, not just sticker. Distributors and consolidators benchmarking Elanco's pull-through against Zoetis' price-led history should plan for a multi-year reset in category mix.

5. The leverage story is finally subordinate. Elanco has carried a debt narrative since the Bayer Animal Health acquisition. Q1 EBITDA at the high end of plan and a raised innovation guide put the operational story in front of the balance-sheet story for the first time in years. That changes how the equity gets owned, and it changes how the company can compete on launch investment.

What Q2 will confirm about Credelio Quattro share gains

Credelio Quattro vs Simparica Trio TRx: Track script-level growth over Q2 and Q3. That's the data point that turns Q1 commentary into a thesis.

Zenrelia head-to-head data: First full year of switching, persistence, and adverse event rates against Apoquel. The JAK class has a complicated safety profile. The market will pay attention.

Livestock segment in Q2: Whether the New World screwworm EUA, granted in late April, drives material Q2 revenue. If the FY26 raise reflects EUA tailwind rather than companion animal compounding, the upgrade should be discounted accordingly.

Zoetis' counter-move: Pricing actions, expanded Simparica Trio indications, or a flagship parasiticide announcement. The defense will tell you whether Zoetis sees Q1 as cyclical or structural.

Net pricing across both: Q2 disclosures from Zoetis and Elanco on parasiticide net price. The category was protected by branded pricing power for a decade. Live competition will test it.

Source: Elanco Q1 2026 release via PR Newswire